Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience. To help address this challenge, Vitestro (Utrecht, Netherlands), a pioneer in medical robotics for automated diagnostic blood collection, has developed Aletta, the world’s first Autonomous Robotic Phlebotomy Device (ARPD), creating a new standard for how blood draws are performed.

Aletta is designed to autonomously perform routine diagnostic blood collection. The system integrates multimodal imaging, advanced robotics, and artificial intelligence to identify suitable veins, guide needle insertion, and collect blood samples with precision and consistency. Aletta is intended to support phlebotomy departments by addressing staffing constraints, reducing operator‑dependent variability, and standardizing specimen quality while enhancing patient experience.

Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

The new website provides detailed information about Vitestro and its Aletta system, outlining the technology, intended diagnostic applications, and role in modern clinical laboratory and outpatient care settings. The site also features Vitestro’s newly released public video, which walks viewers through each step of the Aletta blood draw process, from arm placement at the device to completion of the procedure. The video offers a practical view of autonomous blood collection in routine clinical settings and marks the first time Vitestro has publicly shared a detailed visual explanation of the technology and its clinical workflow.

Aletta is currently CE marked and is available for clinical use in Europe. Vitestro is pursuing U.S. regulatory authorization alongside broader global expansion, with the goal of advancing autonomous diagnostic blood collection globally.

"Our new website and public video reflect a deliberate step toward more open communication and education,” said Toon Overbeeke, Chief Executive Officer of Vitestro. “As we bring autonomous robotic phlebotomy into routine clinical practice, it is essential that healthcare professionals and patients clearly understand how the technology works and how it integrates into real world care delivery. By making our technology and clinical workflow more visible, we are enabling informed adoption, building confidence, and supporting the responsible establishment of a new standard for diagnostic blood collection.”

Related Links
VItestro